Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. - Wikidata - awgldk - TriplyDB

Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease.

Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease.

http://www.wikidata.org/entity/Q30989943

about

Foundations of advanced magnetic resonance imaging.Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models.White matter abnormalities associated with Alzheimer's disease and mild cognitive impairment: a critical review of MRI studies.Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making.Brain imaging in dementia.Use of functional magnetic resonance imaging in the early identification of Alzheimer's disease.Advances in functional magnetic resonance imaging: technology and clinical applications.Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies.MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths.Using NMR approaches to drive the search for new CNS therapeutics.Single-photon emission computed tomography in neurotherapeutics Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation.Graph theoretical analysis of human brain structural networks.Characterization of Atrophic Changes in the Cerebral Cortex Using Fractal Dimensional Analysis.Nearly automatic segmentation of hippocampal subfields in in vivo focal T2-weighted MRI Disrupted small-world brain networks in moderate Alzheimer's disease: a resting-state FMRI study Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects Functional alterations in memory networks in early Alzheimer's disease.The Structured Interview & Scoring Tool-Massachusetts Alzheimer's Disease Research Center (SIST-M): development, reliability, and cross-sectional validation of a brief structured clinical dementia rating interview.Quantization and analysis of hippocampal morphometric changes due to dementia of Alzheimer type using metric distances based on large deformation diffeomorphic metric mapping.Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics Head-to-head comparison of two popular cortical thickness extraction algorithms: a cross-sectional and longitudinal study.Quantitating severity and progression in primary progressive aphasia.Metric distances between hippocampal shapes indicate different rates of change over time in nondemented and demented subjects Detection of cortical thickness correlates of cognitive performance: Reliability across MRI scan sessions, scanners, and field strengths.MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials.Disease staging and milestones.Strategies for molecular imaging dementia and neurodegenerative diseases.Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment.Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine.Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline.Dementia of the Alzheimer type.Regional rates of neocortical atrophy from normal aging to early Alzheimer disease.Texture analysis improves level set segmentation of the anterior abdominal wall.Neuronal networks in Alzheimer's disease.Discriminating cognitive status in Parkinson's disease through functional connectomics and machine learning.Structural magnetic resonance imaging-derived biomarkers for Alzheimer's disease.Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease.Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations.Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias.

P2860

Q30499144-841FB976-809E-4614-ABB7-6D886CD051D1 Q30576007-5271A553-400A-4120-986C-206BC69AE016 Q30620060-083CAE52-7C45-4694-87DF-8C0A90B44E41 Q30989929-390F6108-C243-4EBA-970F-1B81BBFA8124 Q31051218-312BDE96-1182-4417-AC87-10C615F93EF8 Q31111440-71E08944-4215-42FA-810D-D708A1F59E6F Q31117150-332DF9F4-65BF-42DD-BD2C-DC5F33C35F77 Q31143202-9714BD44-112F-46E7-8A7E-F76386D57A42 Q33411170-3ED007FF-59CF-4094-B006-26131A387488 Q33613767-F57F0ACE-BF76-4887-824B-0C3C1D313A49 Q33716200-56401E29-DF85-4B05-B15F-55FC38A8B590 Q33757934-E73FF983-6050-4668-8AAC-B495356F7CB7 Q34001109-9EE78158-75FD-4E18-AB25-42A3AE0F3BCF Q34081180-7FB3070F-7439-4DD5-BB5A-93520C776554 Q34126524-2BA74D9C-964A-4383-A44D-5D66C53BB7C4 Q34211926-725CE6FF-C7B0-4126-A22A-681010B27315 Q34271896-A0389706-7A53-4C68-84B0-406475AA8B66 Q34565270-01471588-A9E5-4325-944B-DEC3FF12ECB6 Q34681067-35D1C134-DB05-45F2-BC10-1EB0BB6EB399 Q34785920-BEC7E592-0333-4654-A637-1737077021CA Q34965949-E38A2E9D-A6E8-4144-A2EC-F6FF99C4F203 Q35189641-DF69B5A0-65D6-4C26-8005-90545767DB5D Q35523051-D04BBBF3-D711-4C87-9FAF-95484F0D20F0 Q35605911-53EB8D93-A0CE-4F53-ABA3-A1CC473B470E Q36276426-8DBA1F35-4092-44B3-8923-761D3D161B1D Q36785972-E32D47B4-C530-4806-BB07-0746CEFF5F57 Q36806639-BB7BC4F5-113A-4D31-A46E-5E2B9E64E8D3 Q36853915-57E615A9-708B-41DF-B47F-3083CC499FC0 Q36969034-A07AC111-AE25-4ADA-A22E-98B3BEB382A2 Q36971142-D7296D77-ED2E-4C52-83EB-E0738D4D7763 Q37194883-BB61D164-A3EE-40BD-B5C2-13DE6A5ED614 Q37219298-8147CFFB-4AD6-47BE-A016-B7B4BBEE59C2 Q37305759-416C593F-825E-4566-8662-FCA54118B30D Q37337093-FC5E133C-B39A-4B29-9BD9-57C86E82B7DA Q37490689-D078BFC2-E22A-4BC8-AFFC-6654E402FAC2 Q37723968-16DB4910-B005-470B-AA45-AAF21C489A55 Q37755134-1F814B18-0ADB-463B-9B9F-D692BC6F55D5 Q37863247-73F90AB7-6A4F-4051-B49B-33EB46A98D48 Q38150708-2A04DAA0-D672-4381-BEC4-8DCCA37B166E Q39346750-2E2C0A2B-842C-4A53-A95A-1893C5D51764

P2860

Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease.

http://www.wikidata.org/entity/Q30989943

description

2005 nî lūn-bûn

@nan

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Neuroimaging biomarkers for cl ...... rapies in Alzheimer's disease.

@ast

Neuroimaging biomarkers for cl ...... rapies in Alzheimer's disease.

@en

type

label

Neuroimaging biomarkers for cl ...... rapies in Alzheimer's disease.

@ast

Neuroimaging biomarkers for cl ...... rapies in Alzheimer's disease.

@en

prefLabel

Neuroimaging biomarkers for cl ...... rapies in Alzheimer's disease.

@ast

Neuroimaging biomarkers for cl ...... rapies in Alzheimer's disease.

@en

P1433

Q30989943-903C9EED-7521-4DE4-9EF2-1AA7843A7C64

P1476

Q30989943-330C67BF-1A9F-4AAD-9F06-D7A2133A857B

P2093

Q30989943-DDD1D070-6AD5-4B82-BE5C-364BEEF95B6B

Q30989943-E164D93F-047E-482F-9E81-AFCA20EBB666

P2860

Q30989943-0466EF19-D035-4FF8-83D2-A56D895CBE6D

Q30989943-0701DB2F-C8E4-43CA-98B5-7A8ECAF70D4F

Q30989943-080E7ED7-B6FA-437C-9B4B-3DE16CC726E2

Q30989943-08C24D59-971E-420C-942F-883CC14F2A55

Q30989943-09F4E8D1-385C-4305-8206-7A64DFC18028

Q30989943-0AA3F26F-DB54-454F-B51D-E1F41AFF4D7E

Q30989943-0B36B7B5-1E6F-43E9-9C1E-71F7D086E4CB

Q30989943-0ED7260C-4B2F-4E16-89B1-A9247E92D39E

Q30989943-0F5B23C4-5C8B-4BDA-A76C-76466AD0E308

Q30989943-11C516B0-4316-4003-9B85-B8AC4A3831FD

P304

Q30989943-D5E65E9D-0EBC-48EA-AED7-4CAEDF8E592C

P31

Q30989943-2115E523-0DC7-444C-BABA-A254D1F1EEF3

P356

Q30989943-9453F8B3-409E-44D2-A3BA-31338C37D614

P433

Q30989943-6AABB144-B696-46D5-9786-2E90E4866EEF

P478

Q30989943-80DFD2D5-99D9-4A72-9324-0AA82A100E1C

P577

Q30989943-A42BF372-27F7-43B7-9EA7-D56975A2B74A

P5875

Q30989943-881C8B99-F6F5-4FE3-AB45-87D0886DBDA1

P698

Q30989943-9B53C2C0-F100-4509-A57D-301F479D885A

P921

Q30989943-1A079D77-5202-466B-A20D-2787DED5747C

Q30989943-7846B5BB-CE79-4D28-B8E5-ED6465E3F97D

Q30989943-A2417C39-1646-411C-AACC-7E50BF7B7566

P932

Q30989943-078A37F5-4EAB-4EAB-A20A-02C2F399A735

P356

NEURORX.2.2.348

P1433

P1476

Neuroimaging biomarkers for cl ...... rapies in Alzheimer's disease.

@en

P2093

Bradford C Dickerson

http://www.w3.org/2001/XMLSchema#string

Reisa A Sperling

http://www.w3.org/2001/XMLSchema#string

P2860

Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials

Voxel-based morphometry--the methods

Mild cognitive impairment: clinical characterization and outcome

A voxel-based morphometric study of ageing in 465 normal adult human brains

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease.

Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia

Alzheimer's disease is a synaptic failure

Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain

Automatically parcellating the human cerebral cortex

P304

348-360

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1602/NEURORX.2.2.348

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7843475

http://www.w3.org/2001/XMLSchema#string

P698

15897955

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

1064996

http://www.w3.org/2001/XMLSchema#string